{"denoms":[{"counts":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"341"},{"groupId":"BG002","value":"512"}],"units":"Participants"}],"groups":[{"description":"All subjects randomized to receive placebo. Approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. Three complete doses were given at approximately 2 week intervals.","id":"BG000","title":"APC-Placebo"},{"description":"All subjects randomized to receive sipuleucel-T. Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consists of 3 doses administered approximately 2 weeks apart.","id":"BG001","title":"Sipuleucel-T"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.0","value":"70.1"},{"groupId":"BG001","spread":"8.9","value":"71.1"},{"groupId":"BG002","spread":"8.9","value":"70.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40","upperLimit":"89","value":"70"},{"groupId":"BG001","lowerLimit":"49","upperLimit":"91","value":"72"},{"groupId":"BG002","lowerLimit":"40","upperLimit":"91","value":"71"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"341"},{"groupId":"BG002","value":"512"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}